Hi [[ session.user.profile.firstName ]]

The hepatitis C conundrum: balancing cost and affordability

Working with QuintilesIMS, we present a digital debate which will offer modellling-based insights into the future of hepatitis C treatment.

Key topics to be discussed include:
– The burden of HCV
– The current market landscape
– The current patient access model and its impact on budget
– Cost efficiencies shown by modelling
– Cure versus lifetime treatment costs
Recorded Nov 22 2016 68 mins
Your place is confirmed,
we'll send you email reminders
Presented by
Ashley Pitcher, Natasha Martin, Paul Tunnah
Presentation preview: The hepatitis C conundrum: balancing cost and affordability

Network with like-minded attendees

  • [[ session.user.profile.displayName ]]
    Add a photo
    • [[ session.user.profile.displayName ]]
    • [[ session.user.profile.jobTitle ]]
    • [[ session.user.profile.companyName ]]
    • [[ userProfileTemplateHelper.getLocation(session.user.profile) ]]
  • [[ card.displayName ]]
    • [[ card.displayName ]]
    • [[ card.jobTitle ]]
    • [[ card.companyName ]]
    • [[ userProfileTemplateHelper.getLocation(card) ]]
  • Channel
  • Channel profile
  • The future of the clinical trial – collaboration and patient centricity May 3 2017 1:00 pm UTC 75 mins
    Jameisha Brown, Eric Delente, Paulo Moreira, Christine Phillips, Andrew McConaghie
    Growing patient influence combined with new technologies and the requirements of new reimbursement models means clinical research is undergoing rapid transformation. Industry is being compelled to move towards more patient centric solutions to keep up with these changes. With healthcare stakeholders in agreement that patient engagement is key to realising the value of clinical trials, regulators, sponsors, CROs, research funders and publishers are all moving towards more patient-focused models.

    With the advent of new methodologies, such as electronic data sources and medical records, recruiting patients for trials now demands extensive collaboration between patients and trial centers to effectively and efficiently run trials. The patient has never been more important.

    To mark Clinical Trials Awareness Week, pharmaphorum, in partnership with INC, will present a live webinar exploring the challenges and solutions of the current environment and how collaboration can benefit research participation, as well as the vital role the patient advocate plays in these matters.
  • Life sciences promotional content management for speed, compliance and insight Live 75 mins
    David Bennett, Andrew McConaghie
    The life sciences landscape is moving at a rapid pace, which in turn is increasing the demands on marketers to create innovative, digital content faster while maintaining industry compliance.

    Veeva Systems recently conducted an annual industry study, focused on content and digital asset management within life sciences. Gleaned from the experiences and opinions of leaders across the life sciences industry, the research uncovers current practices and the industry’s need for more advanced approaches for global marketing and regulatory compliance.

    Join this webinar to hear the key insights from the survey results, and discuss key highlights with host David Bennett, VP Commercial Content Strategy Europe, Veeva.

    From this webinar you will:

    – Learn the current state of commercial content and digital asset management in life sciences promotions
    – Garner an understanding of how your organization compares to the industry
    – Understand how to accelerate your content across the digital supply chain
  • When small becomes big: orphan medicines, advances, access and affordability Recorded: Apr 10 2017 75 mins
    Alastair Kent OBE, Malcolm Qualie, Sheela Upadhyaya, Sarah Rickwood, Moderated by Paul Tunnah
    Over the past few years there has been a shift in the European pharmaceutical market landscape, with a rise in specialty medicines for diseases with narrow patient populations. Indeed, QuintilesIMS forecasts that, between 2013 and 2018, 94% of list price value growth will be in specialty medicines – with orphan drugs at the forefront of this trend.
    On 10 April 2017, QuintilesIMS, in partnership with pharmaphorum presents a unique digital debate, bringing together a panel of senior industry experts, including participants from NICE, NHS England and Genetic Alliance UK to explore the pillars of commercial success for orphan drugs in Europe in the context of changes in reimbursement processes and broader future challenges, like Brexit.
  • Unlocking the value of pharmacists to reach the right patients and consumers Recorded: Mar 29 2017 70 mins
    Pierre-Yves Boisvert, Paulien Schul, Nina Felton and Andrew McConaghie
    Pharmacists are highly trained healthcare professionals who have a deep understanding of medicines and daily contact with patients and consumers. This puts them in a unique position in terms of being able to maximise the benefits that patients get from their medicines – however, healthcare systems and pharmaceutical companies frequently overlook this potential.
    Pharmacists are especially well placed to help patients with multiple long-term conditions manage their health and medications, and pharmacist-led interventions have been shown to have a very significant impact on compliance and disease management in the community.
    We present a webinar debate in which our expert panel will discuss how pharmaceutical companies can work in collaboration with pharmacists in Europe to help patients make the most of their medicines, help generate data to prove the value of these interventions, and above all get the right medicine to the right patients and consumers.
    Join us and the PHOENIX group as we look at the practical steps needed to make this a reality. Key topics to be discussed include:
    •The challenges of identifying the right patient population across European markets
    •Understanding how pharmacists can play a greater role in patient care, e.g. improved adherence and outcomes
    •How optimum use of pharmacy level information can contribute to providing ‘real world’ evidence of treatments
  • Approval and access: Overcoming the final hurdle of drug development Recorded: Mar 10 2017 61 mins
    Professor Luca Pani, University of Miami, Angelika Joos,MSD (Europe) Inc. Ana Palma, Sobi, Belgium
    2017 is once again a year of significant change for pharma market access in Europe, with affordability on the agenda for almost every country in the region. There is a move toward greater collaboration in health technology assessment and more transparency between countries for pricing, therapeutic protocols and and details of negotiations with drug manufacturers. We also see member states working to understand the process of enabling cost-effective patient access to personalised and high-cost treatments, such as new oncology combination therapies, antibiotics and stem cell therapies, which offer the promise of efficacy in key disease areas.

    With market access being referred to as the “fourth hurdle” in drug development (beyond efficacy, safety and quality), it is vital that the requirements for both approval and access are addressed early in the process. Parallel scientific advice from HTA bodies and regulators is increasing to deliver tangible and successful strategies, but is the process smooth enough to overcome the challenges from both sides?

    pharmaphorum in partnership with DIA will be hosting an expert panel debating the best way forward for life sciences companies, payers and providers in this emerging European market access paradigm.

    Join our webinar to hear from experts in industry and healthcare discussing the challenges and solutions of access in the changing European market.
    Topics up for discussion include:
    •Integrating HTA and regulatory strategy – the best way forward
    •Regional variation and implication – how to efficiently and effectively navigate EU market access
    •Proving value – how to leverage real world evidence to meet increasing demands for observational data
    •Future proofing market access – how to improve upon evidence generation and use technology effectively and competitively
  • Taking health wearables to the next level – where is the market heading? Recorded: Dec 8 2016 63 mins
    Roberto Slepetys, Martin Pöhlchen, Gayatri Gopal, Andrew McConaghie
    With rising healthcare costs, more informed and engaged patients, and advancing technology, health wearables have seen a significant uptake in recent years. However, the full potential of health wearables has yet to be recognised and there are still challenges to be resolved. What needs to be done on the regulatory, technical and healthcare side to take health wearables to the next level?
    In this webinar, experts from the life sciences and technology industries discuss their views on the current state and future developments of health wearables, including:
    – The user perspective: perception, adoption and expectations today and tomorrow
    – The technology perspective: biggest successes and most room for improvements
    – The societal and regulatory perspective: cost and risks versus benefits and opportunities
  • The Patient Centric Launch – business insights key to success in Europe Recorded: Nov 30 2016 61 mins
    Nina Felton, Nick Cooper Larry R Smith II and Andrew McConaghie (moderator)
    Join us and PHOENIX group as we delve into the concept of current launch excellence and the role of patient insights in overcoming the multiple challenges the industry currently faces.
    Key topics to be discussed include:
    – The challenges of launching a product in Europe
    – How pharma can improve its understanding of the process through the use of business intelligence
    – How insights from new data can be applied to the process of launch excellence
    – The role of real-world data in launch strategy
    – The downstream effect of applying real-world data to product launch on patient outcomes.
  • The hepatitis C conundrum: balancing cost and affordability Recorded: Nov 22 2016 68 mins
    Ashley Pitcher, Natasha Martin, Paul Tunnah
    Working with QuintilesIMS, we present a digital debate which will offer modellling-based insights into the future of hepatitis C treatment.

    Key topics to be discussed include:
    – The burden of HCV
    – The current market landscape
    – The current patient access model and its impact on budget
    – Cost efficiencies shown by modelling
    – Cure versus lifetime treatment costs
  • Demand Assessment Research: adopting insights from behavioural economics Recorded: Nov 16 2016 52 mins
    Duncan Munro and Andrew McConaghie
    Over the past 20 years, behavioural economics has identified factors that influence and determine how people behave, including alternative decision-making pathways and many cognitive biases and heuristics. Taking account of these helps to build a clear view of how healthcare customers think and behave in relation to your product in the real world.
    This short masterclass explores ‘quantitative demand assessment research’ – what it is and how insights from behavioural economics can improve the application of this important tool in pharmaceutical market research.
    The masterclass will:
    •Introduce demand assessment research and why it is important to healthcare market research
    •Discuss how insights from behavioural economics can improve quantitative demand assessment market research
    •Highlight a range of techniques using behavioural economics that help you build a more accurate picture of your customers and market.
  • Finding a cure: Getting the best Brexit deal for Britain's life sciences Recorded: Nov 2 2016 66 mins
    Paul Tunnah, Rt Hon Stephen Dorrell, Sarah Rickwood, Lesley Galloway, Angela McFarlane, Prof. Richard Barker, OBE and more
    Senior level expert panel debate on the likely impacts of a hard v soft Brexit for life sciences companies in Britain.
  • Getting closer to your customer through video technology Recorded: Sep 14 2016 61 mins
    Damian Eade, Tim Williams, Andrew McConaghie
    Video content accounted for 64% of all the world’s internet traffic in 2014 and is expected to grow to 80% by 2019. As the way in which we connect and digest information evolves, high quality mobile video capture and advanced digital analysis offers ever more authentic, intimate and rich insights into the customers’ world. This webinar will focus on:
    – How emerging technology can enable us to realise the true value of ‘video data’ in our analysis and beyond
    – How mobile technology can be used to get you closer to your customers and their real world experiences right from the earliest stages in product development
    – How real world video content can engage your key stakeholders and ensure customer insights drive action
  • Measuring the cost of the right interventions in diabetes Recorded: Sep 8 2016 69 mins
    John Grumitt, IDF/Diabetes UK, Prof Michael Trenell, Newcastle University, Dr Phil McEwan
    Diabetes is one of the most prevalent and most costly conditions worldwide – with a prevalence equating to 8.5% of the global population. Due to the complex nature of diabetes, with numerous co-morbidities and its asymptomatic nature, accurately modelling and therefore discerning which interventions are most effective, in terms of cost and patient impact is an equally complicated process.

    This webinar will explore the patient pathway and how effective modelling – when pharma works together with healthcare stakeholders – can improve outcomes for both patients and the healthcare system as a whole.
  • Cancer Treatment Access: Right Strategy, Right Approach, Right Outcomes Recorded: Aug 2 2016 69 mins
    Malcolm Qualie, NHS England, Nina Pinwill, NICE, Katie Pascoe, ABPI, Angela McFarlane, IMS Health Toby Gosden, IMS Health
    Join us for a one-hour live debate on Cancer Treatment Access: Right Strategy, Right Approach, Right Outcomes.

    To ensure funding and patient access to innovative cancer therapies, industry now have to navigate a new English cancer-treatment funding ecosystem, engaging with NICE and NHS England to realise a yes, no or conditional arrangement.

    How can oncology treatments achieve a positive NICE appraisal in the new world and what will the mechanics of RWE be in the event of conditional funding via the reformed cancer drugs fund?
  • What do the upcoming changes to England's pharmacy funding mean? Recorded: Jul 21 2016 67 mins
    John Smith, PAGB, Rob Darracott, Pharmacy Voice, Sandra Gidley, English Pharmacy Board
    New measures proposed by the Government will impact community pharmacies across the UK; the biggest change of this nature in decades. The impact will go beyond community pharmacies as other stakeholders also feel the pressure.

    UK pharmacies already support more inhabitants per pharmacy than other major European markets; how will this funding change impact how patients are cared for in the community? How will pharmacy suppliers, such as consumer health companies, operate in the increasingly cost constrained and competitive environment?

    Working with our partner, IMS Health, we present an interactive webinar to share market insight on the potential impact and a live discussion with critical stakeholders of this change. Hear directly from key stakeholders about their thoughts of how the changes will play out, and what this means for you in your sector.
  • BREXIT: What's next for pharma? Recorded: Jul 14 2016 71 mins
    Stephen Dorrell, Chair NHS Confederation, Leslie Galloway, EMIG, Prof. Mike Bewick, prev NHS England, Dr Rick Greville, ABPI
    The pharmaceutical industry is one of the largest contributing industries to the UK’s balance of trade, and the UK Nation Health Service (NHS) is the fifth largest employer in the world.

    Although the process of exit for the UK from the EU has now to be triggered by invoking article 50, the post-Brexit calendar is a firestorm of uncertainty. The uncertainty could potentially have a chilling effect on global pharma investment in the UK, but are the issues that will impact Pharma - a jewel in the crown of UKPLC - being heard in Westminster - and Brussels?

    In order to better understand the potential impact of Brexit on both pharma and healthcare in the UK, we are working with specialist IMS Health to bring a unique debate in which a hand-picked panel of experts will discuss and analyse:

    The impact of Brexit on UK Healthcare
    The ramification of Brexit for pharma in the UK
    What does the Brexit scenario mean for global pharma?
  • Establishing a Solid Foundation for Digital Transformation Recorded: Jul 12 2016 63 mins
    Alexandre Gultzgoff, Deputy Director, IT, Sanofi Pasteur MSD Antoine Blanc, Commercial Excellence Director, Sanofi Pasteur MS
    Sanofi Pasteur MSD is transforming its commercial organisation and remodeling its approach to customer engagement. Hear from Sanofi Pasteur MSD’s Alexandre Gultzgoff, Deputy Director, IT, and Antoine Blanc, Commercial Excellence Director, as they share first hand insights on how they are transforming their European commercial operations and improving customer engagement. Learn from their best practice as they share Sanofi Pasteur MSD’s:
    · Vision and strategy for digital transformation
    · Digital channels (CLM, email) to improve customer engagement
    · Deployment of a digital supply chain in ensuring fresh content to channels and content reuse
  • What's next for patient-centricity? How do we know when we are patient-centric? Recorded: Jul 5 2016 63 mins
    Jo Fearnhead-Wymbs, Ashfield Healthcare, Anita Osborn, Ashfield Clinical, Andrew Schorr, Patient Power, Paul Robinson, MS
    This webinar will delve into the challenges that pharma face when looking at their patient-centricity strategy, and the opportunities that exist with this approach. We will explore the key motivators for this approach, and steps to overcome the internal and external barriers, and most importantly – how do pharma companies know when they have become truly patient-centric? How should they measure the impact of their strategy through the lifecycle of a drug and their business as a whole?
  • Transforming Medical Affairs with fact-based solutions and improved compliance Recorded: Jun 28 2016 67 mins
    Blake Morrison; Harleen Parmar; Seth Whitelaw; Paul Tunnah
    In today’s competitive, highly regulated environment, product success is dependent upon data and fact-based decision making. More and more, Medical Affairs teams play a pivotal role in education pre- and post-launch, yet the explosion of big data in healthcare is changing how we make value-based decisions that are critical to success.

    This webinar will explore the challenges Medical Affairs teams have finding a repeatable, objective and compliant solution to identify and manage their strategic programs.

    With a wealth of information available, it can be difficult to sort through data and understand what is important to incorporate into research and strategy. In this session you’ll hear needs and use cases for having a robust data strategy when it comes to Medical Affairs success. The panelists will share best practices for making fact-based decisions that meet compliance restrictions, using powerful market insights gained from multiple data sources, to optimize strategic planning and ultimately drive product success.
  • Social medical: The social media buzz around ASCO 2016 Recorded: Jun 27 2016 64 mins
    Paul Tunnah, Dr Mike Thompson, Dr Richard Simcock, Silja Chouquet, Andrew Schorr
    The ASCO Annual Meeting, the largest global oncology meeting and increasingly the centre of a kaleidoscope of social media coverage each year.

    As a snapshot, 2014 saw 40,000 tweets and 140m+ impressions over the conference days, 2015 grew to 60,000 tweets and 250m+ impressions and the 2016 buzz is already louder and more plentiful than last year.

    This webinar will examine the conversation around ASCO 2016, its relationship with ASCO, value to and involvement from stakeholder groups and how it will potentially continue to evolve into 2017.
  • What does 'the cloud' mean for pharma? Recorded: May 4 2016 65 mins
    Athula Herath (Novartis), Umang Patel (Babylon Health), Peter Emberson (UK Pharma IT Forum), Paul Tunnah (pharmaphorum)
    A unique Q&A session/open forum panel debate.

    It is likely that you interact with ‘the cloud’ on various devices, multiple times throughout the day. However, for pharma we have only just scratched the surface regarding what the cloud can offer in terms of security, connectivity and efficacy. ‘Business analytics’ and ‘cloud’ are often misunderstood.

    To answer this, pharmaphorum, in conjunction with industry stalwarts Equinix, present a unique Q&A event, offering the opportunity to ask any questions you may have around what the cloud can do, and how to remain compliant in utilising this technology.

    This debate is an open forum and the expert panel will offer insight about interaction between the cloud and pharma with a particular focus on:
    • Patient outcomes – The cloud and patients, what are the routes to improving outcomes?
    • Internet of things – As the ways to gather data and interact increase exponentially, how does the cloud support this? What are the opportunities and can we eliminate the risk?
    • Data and security – How to achieve compliance almost automatically.
    • Collaboration – Why and how the cloud enables true partnership working.
Thought leadership webinars within the pharmaceutical industry
pharmaphorum provides a digital podium for communicating thought leadership and innovation within pharma. Our webinars bring together different stakeholders from across the healthcare spectrum to drive fresh thinking and novel solutions that deliver better outcomes for patients.

Embed in website or blog

Successfully added emails: 0
Remove all
  • Title: The hepatitis C conundrum: balancing cost and affordability
  • Live at: Nov 22 2016 3:30 pm
  • Presented by: Ashley Pitcher, Natasha Martin, Paul Tunnah
  • From:
Your email has been sent.
or close